Similar articles for PMID: 25650219

Year	Number of Results
1999	1
2000	2
2004	2
2006	1
2007	1
2008	1
2009	2
2010	2
2011	2
2012	6
2013	10
2014	18
2015	21
2016	8
2017	7
2018	3
2024	0

1

Levy A. Levy A. Clin Med (Lond). 2015 Feb;15(1):107-8. doi: 10.7861/clinmedicine.15-1-106b. Clin Med (Lond). 2015. PMID: 25650219 Free PMC article. No abstract available.

2

Neutropenic sepsis: a potentially life-threatening complication of chemotherapy.

Ford A, Marshall E. Ford A, et al. Clin Med (Lond). 2014 Oct;14(5):538-42. doi: 10.7861/clinmedicine.14-5-538. Clin Med (Lond). 2014. PMID: 25301919 Free PMC article. No abstract available.

3

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.

Lambertini M, Ferreira AR, Del Mastro L, Danesi R, Pronzato P. Lambertini M, et al. Expert Opin Biol Ther. 2015;15(12):1799-817. doi: 10.1517/14712598.2015.1101063. Epub 2015 Oct 21. Expert Opin Biol Ther. 2015. PMID: 26488491 Review.

4

Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle.

Li X, Luthra R, Morrow PK, Fisher MD, Reiner M, Barron RL, Langeberg WJ. Li X, et al. J Oncol Pharm Pract. 2016 Oct;22(5):679-89. doi: 10.1177/1078155215603229. Epub 2015 Sep 15. J Oncol Pharm Pract. 2016. PMID: 26378158

5

A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study.

Bozcuk H, Yıldız M, Artaç M, Kocer M, Kaya Ç, Ulukal E, Ay S, Kılıç MP, Şimşek EH, Kılıçkaya P, Uçar S, Coskun HS, Savas B. Bozcuk H, et al. Support Care Cancer. 2015 Jun;23(6):1759-67. doi: 10.1007/s00520-014-2531-6. Epub 2014 Nov 30. Support Care Cancer. 2015. PMID: 25433439

6

[Impact of early lymphopenia on the risk of febrile neutropenia and hematological toxicity].

Ben Nasr S, Zriba S, Kacem K, Yahyaoui Y, El Benna H, Mansouri R, Ben Lakhal R, Meddeb B. Ben Nasr S, et al. Tunis Med. 2015 May;93(5):283-6. Tunis Med. 2015. PMID: 26578043 Free article. French.

7

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.

Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Hashiguchi Y, et al. Anticancer Drugs. 2015 Nov;26(10):1054-60. doi: 10.1097/CAD.0000000000000279. Anticancer Drugs. 2015. PMID: 26267078 Free PMC article.

8

Acute Oncology Care: A narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors.

Knight T, Ahn S, Rice TW, Cooksley T. Knight T, et al. Eur J Intern Med. 2017 Nov;45:59-65. doi: 10.1016/j.ejim.2017.09.025. Epub 2017 Oct 6. Eur J Intern Med. 2017. PMID: 28993098 Review.

9

Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.

Lalami Y, Klastersky J. Lalami Y, et al. Crit Rev Oncol Hematol. 2017 Dec;120:163-179. doi: 10.1016/j.critrevonc.2017.11.005. Epub 2017 Nov 11. Crit Rev Oncol Hematol. 2017. PMID: 29198330 Review.

10

Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.

Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Weycker D, et al. J Oncol Pharm Pract. 2014 Jun;20(3):190-8. doi: 10.1177/1078155213492450. Epub 2013 Jul 2. J Oncol Pharm Pract. 2014. PMID: 23824496

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

71 results

Results by year